Quality of life, Body image, and psychiatric implications in patients with urn trauma: preliminary study of the Italian version of Burn Specific Heal…

2010

Burn patients may suffer both physical and psychopatological consequences and their quality of life and the presence of psychopathological symptoms should be evacuate. The Burn Specific Health Scale-Brief (BSHS-B) is a tried and test-instrument for assessing burn patients’ quality of life. The aim of this study is to propose the Italian translation of BSHS-B and presents the preliminary results of an exploratory study. The Italian version of BSHS-B was administered to a sample group of 50 burn victims. Reliability was verified by Cronbach’s alpha, and construct validity was evaluated through correlation with the Short Form 36 Health Survey Questionnaire (SF-36) and the Self-report Symptom I…

ASSOCIATION BETWEEN COPING STRATEGIES AND PSYCHOLOGICAL ADJUSTMENT AFTER SMALL BURN INJURIES. A CROSS-SECTIONAL STUDY

2017

Objective: This study aimed at describing the coping strategies used by patients of small burns (<= 20% body surface area) at the early stage of rehabilitation process and to analyze the effect of coping strategies and body image dissatisfaction on psychiatric symptoms and quality of life.Method: Sixty-nine patients firstly admitted to an out-patient burn unit were involved in the study. Coping response to burn trauma was investigated using the Brief-COPE, while the Short-Form 36 Health Survey, the Self-report Clinical Inventory, and the Body Uneasiness Test were used respectively to assess post-burn quality of life, psychiatric symptoms, and body image dissatisfaction.Results: Avoidant …

Qualità di Vita, immagine del corpo e complicanze psichiatriche in pazienti con trauma da ustione

2009

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomized, double blind, placebo controlled, phase III study.

2015

Objective To assess the efficacy of recombinant human erythropoietin (rhEPO) in amyotrophic lateral sclerosis (ALS). Methods Patients with probable laboratory-supported, probable or definite ALS were enrolled by 25 Italian centres and randomly assigned (1:1) to receive intravenous rhEPO 40 000 IU or placebo fortnightly as add-on treatment to riluzole 100 mg daily for 12 months. The primary composite outcome was survival, tracheotomy or >23 h non-invasive ventilation (NIV). Secondary outcomes were ALSFRS-R, slow vital capacity (sVC) and quality of life (ALSAQ-40) decline. Tolerability was evaluated analysing adverse events (AEs) causing withdrawal. The randomisation sequence was computer-…